These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 26115122)

  • 1. The Effect of MicroRNA-124 Overexpression on Anti-Tumor Drug Sensitivity.
    Chen SM; Chou WC; Hu LY; Hsiung CN; Chu HW; Huang YL; Hsu HM; Yu JC; Shen CY
    PLoS One; 2015; 10(6):e0128472. PubMed ID: 26115122
    [TBL] [Abstract][Full Text] [Related]  

  • 2. c-MYC suppresses BIN1 to release poly(ADP-ribose) polymerase 1: a mechanism by which cancer cells acquire cisplatin resistance.
    Pyndiah S; Tanida S; Ahmed KM; Cassimere EK; Choe C; Sakamuro D
    Sci Signal; 2011 Mar; 4(166):ra19. PubMed ID: 21447800
    [TBL] [Abstract][Full Text] [Related]  

  • 3. miR-218 targets survivin and regulates resistance to chemotherapeutics in breast cancer.
    Hu Y; Xu K; Yagüe E
    Breast Cancer Res Treat; 2015 Jun; 151(2):269-80. PubMed ID: 25900794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.
    Lai J; Yang H; Zhu Y; Ruan M; Huang Y; Zhang Q
    BMC Cancer; 2019 Jun; 19(1):602. PubMed ID: 31215481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. MicroRNA-140 impedes DNA repair by targeting FEN1 and enhances chemotherapeutic response in breast cancer.
    Lu X; Liu R; Wang M; Kumar AK; Pan F; He L; Hu Z; Guo Z
    Oncogene; 2020 Jan; 39(1):234-247. PubMed ID: 31471584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells.
    Min A; Im SA; Kim DK; Song SH; Kim HJ; Lee KH; Kim TY; Han SW; Oh DY; Kim TY; O'Connor MJ; Bang YJ
    Breast Cancer Res; 2015 Mar; 17():33. PubMed ID: 25888415
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CD44 is a direct target of miR-199a-3p and contributes to aggressive progression in osteosarcoma.
    Gao Y; Feng Y; Shen JK; Lin M; Choy E; Cote GM; Harmon DC; Mankin HJ; Hornicek FJ; Duan Z
    Sci Rep; 2015 Jun; 5():11365. PubMed ID: 26079799
    [TBL] [Abstract][Full Text] [Related]  

  • 8. MicroRNA-125b upregulation confers aromatase inhibitor resistance and is a novel marker of poor prognosis in breast cancer.
    Vilquin P; Donini CF; Villedieu M; Grisard E; Corbo L; Bachelot T; Vendrell JA; Cohen PA
    Breast Cancer Res; 2015 Jan; 17(1):13. PubMed ID: 25633049
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Down-regulation of PARP1 by miR-891b sensitizes human breast cancer cells to alkylating chemotherapeutic drugs.
    Xu S; Zhao C; Jia Z; Wang X; Han Y; Yang Z
    Arch Gynecol Obstet; 2017 Sep; 296(3):543-549. PubMed ID: 28660502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. c-MYC Generates Repair Errors via Increased Transcription of Alternative-NHEJ Factors, LIG3 and PARP1, in Tyrosine Kinase-Activated Leukemias.
    Muvarak N; Kelley S; Robert C; Baer MR; Perrotti D; Gambacorti-Passerini C; Civin C; Scheibner K; Rassool FV
    Mol Cancer Res; 2015 Apr; 13(4):699-712. PubMed ID: 25828893
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The nuclear expression of poly (ADP-ribose) polymerase-1 (PARP1) in invasive primary breast tumors is associated with chemotherapy sensitivity.
    Zhai L; Li S; Li X; Li H; Gu F; Guo X; Liu F; Zhang X; Fu L
    Pathol Res Pract; 2015 Feb; 211(2):130-7. PubMed ID: 25480692
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MiR-223 promotes the cisplatin resistance of human gastric cancer cells via regulating cell cycle by targeting FBXW7.
    Zhou X; Jin W; Jia H; Yan J; Zhang G
    J Exp Clin Cancer Res; 2015 Mar; 34(1):28. PubMed ID: 25888377
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PARP1 impact on DNA repair of platinum adducts: preclinical and clinical read-outs.
    Olaussen KA; Adam J; Vanhecke E; Vielh P; Pirker R; Friboulet L; Popper H; Robin A; Commo F; Thomale J; Kayitalire L; Filipits M; Le Chevalier T; André F; Brambilla E; Soria JC
    Lung Cancer; 2013 May; 80(2):216-22. PubMed ID: 23410825
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1.
    Zhang Y; Duan G; Feng S
    Biochem Biophys Res Commun; 2015 Apr; 459(3):367-73. PubMed ID: 25727016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
    Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
    BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MicroRNA-133b targets glutathione S-transferase π expression to increase ovarian cancer cell sensitivity to chemotherapy drugs.
    Chen S; Jiao JW; Sun KX; Zong ZH; Zhao Y
    Drug Des Devel Ther; 2015; 9():5225-35. PubMed ID: 26396496
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
    Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
    Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
    [TBL] [Abstract][Full Text] [Related]  

  • 19. miR-9 regulation of BRCA1 and ovarian cancer sensitivity to cisplatin and PARP inhibition.
    Sun C; Li N; Yang Z; Zhou B; He Y; Weng D; Fang Y; Wu P; Chen P; Yang X; Ma D; Zhou J; Chen G
    J Natl Cancer Inst; 2013 Nov; 105(22):1750-8. PubMed ID: 24168967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. miRNA-34a is associated with docetaxel resistance in human breast cancer cells.
    Kastl L; Brown I; Schofield AC
    Breast Cancer Res Treat; 2012 Jan; 131(2):445-54. PubMed ID: 21399894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.